TY - JOUR
T1 - Somatic mosaicism and variant frequency detected by next-generation sequencing in X-linked Alport syndrome
AU - Fu, Xue Jun
AU - Nozu, Kandai
AU - Kaito, Hiroshi
AU - Ninchoji, Takeshi
AU - Morisada, Naoya
AU - Nakanishi, Koichi
AU - Yoshikawa, Norishige
AU - Ohtsubo, Hiromi
AU - Matsunoshita, Natsuki
AU - Kamiyoshi, Naohiro
AU - Matsumura, Chieko
AU - Takagi, Nobuaki
AU - Maekawa, Kohei
AU - Taniguchi-Ikeda, Mariko
AU - Iijima, Kazumoto
N1 - Funding Information:
This study was supported by a grant from the Ministry of Health, Labour, and Welfare of Japan for Research on Rare Intractable Diseases in Kidney and Urinary Tract (H24-nanchitou (nan)-ippan-041 to KI) in the ‘Research on Measures for Intractable Diseases’ Project; a Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Subject ID: 25893131 to KN); and a grant from the Mother and Child Health Foundation (Subject ID: 25-7 to KN).
Publisher Copyright:
© 2016 Macmillan Publishers Limited.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - X-linked Alport syndrome (XLAS) is a progressive, hereditary nephropathy. Although men with XLAS usually develop end-stage renal disease before 30 years of age, some men show a milder phenotype and develop end-stage renal disease later in life. However, the molecular mechanisms associated with this milder phenotype have not been fully identified. We genetically diagnosed 186 patients with suspected XLAS between January 2006 and August 2014. Genetic examination involved: (1) extraction and analysis of genomic DNA using PCR and direct sequencing using Sanger's method and (2) next-generation sequencing to detect variant allele frequencies. We identified somatic mosaic variants in the type VI collagen, α5 gene (COL4A5) in four patients. Interestingly, two of these four patients with variant frequencies in kidney biopsies or urinary sediment cells of ≥50% showed hematuria and moderate proteinuria, whereas the other two with variant frequencies of <50% were asymptomatic or only had hematuria. De novo variants can occur even in asymptomatic male cases of XLAS resulting in mosaicism, with important implications for genetic counseling. This is the first study to show a tendency between the variant allele frequency and disease severity in male XLAS patients with somatic mosaic variants in COL4A5. Although this is a very rare status of somatic mosaicism, further analysis is needed to show this correlation in a larger population.
AB - X-linked Alport syndrome (XLAS) is a progressive, hereditary nephropathy. Although men with XLAS usually develop end-stage renal disease before 30 years of age, some men show a milder phenotype and develop end-stage renal disease later in life. However, the molecular mechanisms associated with this milder phenotype have not been fully identified. We genetically diagnosed 186 patients with suspected XLAS between January 2006 and August 2014. Genetic examination involved: (1) extraction and analysis of genomic DNA using PCR and direct sequencing using Sanger's method and (2) next-generation sequencing to detect variant allele frequencies. We identified somatic mosaic variants in the type VI collagen, α5 gene (COL4A5) in four patients. Interestingly, two of these four patients with variant frequencies in kidney biopsies or urinary sediment cells of ≥50% showed hematuria and moderate proteinuria, whereas the other two with variant frequencies of <50% were asymptomatic or only had hematuria. De novo variants can occur even in asymptomatic male cases of XLAS resulting in mosaicism, with important implications for genetic counseling. This is the first study to show a tendency between the variant allele frequency and disease severity in male XLAS patients with somatic mosaic variants in COL4A5. Although this is a very rare status of somatic mosaicism, further analysis is needed to show this correlation in a larger population.
UR - http://www.scopus.com/inward/record.url?scp=84958105864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958105864&partnerID=8YFLogxK
U2 - 10.1038/ejhg.2015.113
DO - 10.1038/ejhg.2015.113
M3 - Article
C2 - 26014433
AN - SCOPUS:84958105864
SN - 1018-4813
VL - 24
SP - 387
EP - 391
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 3
ER -